Pattern of Local Recurrence After I-125 Episcleral Brachytherapy for Uveal Melanoma in a Spanish Referral Ocular Oncology Unit

被引:10
|
作者
Sanchez-Tabernero, Sara [1 ]
Garcia-Alvarez, Ciro [2 ]
Munoz-Moreno, Ma Fe [3 ]
Diezhandino, Patricia [4 ]
Alonso-Martinez, Pilar [4 ]
de Frutos-Baraja, Jesus M. [4 ]
Lopez-Lara, Francisco [4 ]
Saornil, Maria A. [2 ]
机构
[1] Hosp Clin Univ Valladolid, Serv Oftalmol, Av Raman y Cajal 12,8B, Valladolid 47003, Spain
[2] Hosp Clin Univ Valladolid, Serv Oftalmol, Unidad Tumores Intraoculares Adulto, Valladolid, Spain
[3] Hosp Clin Univ Valladolid, Unidad Invest, Unidad Tumores Intraoculares Adulto, Valladolid, Spain
[4] Hosp Clin Univ Valladolid, Serv Oncol Radioterap, Unidad Tumores Intraoculares Adulto, Valladolid, Spain
关键词
COMS RANDOMIZED TRIAL; CILIARY BODY; IODINE-125; BRACHYTHERAPY; CHOROIDAL MELANOMA; TREATMENT FAILURE; SURVIVAL; TUMOR; METASTASIS; PLAQUE; MORTALITY;
D O I
10.1016/j.ajo.2017.05.019
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To describe the time, frequency, and clinical characteristics of treatment failure after I-125 brachytherapy in patients with uveal melanoma treated and followed in a Spanish referral ocular oncology unit. DESIGN: Prospective, consecutive, interventional case series. METHODS: Patients diagnosed with uveal melanoma from 1995 to 2016 and treated with episcleral brachytherapy were included. Demographic data collection, ophthalmic evaluation, ultrasound scan, and systemic studies were performed at baseline, every 6 months thereafter for 5 years, and subsequently at annual intervals. Recurrence was defined as presence of tumor growth after treatment. Baseline analysis was performed by descriptive methods and survival by Kaplan-Meier curves. RESULTS: From 732 patients diagnosed with uveal melanoma, 311 were treated with brachytherapy. In the follow-up (mean 79 months, standard deviation = 55), 16 local tumor recurrences (5.1%) were detected. All relapsing patients had choroidal tumors and 15 presented with visual symptoms. All patients were treated with I-125 brachytherapy, and 2 received associated transpupillary thermotherapy. All the eyes were enucleated after recurrence. Kaplan-Meier analysis showed a mean time of recurrence of 3.7 years (standard deviation = 2.94 years, ranging from 1 to 12 years). Three patients had metastasis in the follow-up. Kaplan-Meier analysis showed worse survival for patients with recurrence. CONCLUSION: Local treatment failure was a relatively infrequent event after I-125 brachytherapy in our series. Recurrences appear not only early but also late in the follow-up. They do not have a distinctive clinical pattern and are associated with poorer survival. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 42 条
  • [21] A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma
    Miguel, David
    de Frutos, Jesus Maria
    Alonso, Pilar
    Garcia-Alvarez, Ciro
    Saornil, Maria Antonia
    Diezhandino, Patricia
    Garavis, Maria Isabel
    Valencia, Patricia
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2023, 15 (05) : 350 - 356
  • [22] Long Term Visual Outcomes for Ocular Melanoma Patients Treated With I-125 Brachytherapy Eye Plaques
    Engel, Steven
    Dermarkarian, Christopher
    Markoe, Arnold
    Dean, Mary
    Yechieli, Raphael
    Harbour, William
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (02): : E45 - E46
  • [23] I-125 plaque therapy for uveal melanoma - Analysis of the impact of time and dose factors on local control
    Quivey, JM
    Augsburger, J
    Snelling, L
    Brady, LW
    CANCER, 1996, 77 (11) : 2356 - 2362
  • [24] I-125 Brachytherapy for Choroidal Melanoma Photographic and Angiographic Abnormalities: The Collaborative Ocular Melanoma Study: COMS Report No. 30
    Boldt, H. Culver
    Melia, B. Michele
    Liu, Judy C.
    Reynolds, Sandra M.
    OPHTHALMOLOGY, 2009, 116 (01) : 106 - 115
  • [25] Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5
    Binder, Christina
    Mruthyunjaya, Prithvi
    Schefler, Amy C.
    Seider, Michael I.
    Crilly, Richard
    Hung, Arthur
    Meltsner, Sheridan
    Mowery, Yvonne
    Kirsch, David G.
    Teh, Bin S.
    Jennelle, Richard L. S.
    Studenski, Matthew T.
    Liu, Wu
    Lee, Choonik
    Hayman, James A.
    Kastner, Brian
    Hadsell, Michael
    Skalet, Alison H.
    OCULAR ONCOLOGY AND PATHOLOGY, 2020, 6 (03) : 210 - 218
  • [26] Evaluating the Relationship Between Prescription Dose and Overall Survival Among Patients Treated With I-125 Brachytherapy for Posterior Uveal Melanoma
    Perez, B.
    Vajzovic, L.
    Mettu, P.
    Rivera, D.
    Alkaissi, A.
    Steffey, B. A.
    Stinnett, S.
    Marks, L. B.
    Mruthyunjaya, P.
    Kirsch, D. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S197 - S197
  • [27] Re-treatment of locally recurrent uveal melanoma with repeat eye plaque I-125 brachytherapy: A single institution experience
    Tran, Kevin
    Schefler, Amy C.
    Chevli, Neil
    Hasegawa, Naomi
    Ivey, Forrest
    Olek, Devin
    Bretana, Maria E.
    Pino, Ramiro
    Butler, Edward Brian
    Teh, Bin S.
    BRACHYTHERAPY, 2024, 23 (05) : 604 - 609
  • [28] Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma
    Jensen, AW
    Petersen, IA
    Kline, RW
    Stafford, SL
    Schomberg, PJ
    Robertson, DM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (01): : 101 - 108
  • [29] Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy
    Wisely, C. Ellis
    Hadzialnnetovic, Mersiha
    Reem, Rachel E.
    Hade, Erinn M.
    Nag, Subir
    Davidorf, Frederick H.
    Martin, Douglas
    Cebulla, Colleen M.
    BRACHYTHERAPY, 2016, 15 (01) : 12 - 22
  • [30] Reduced blood flow by laser speckle flowgraphy after 125I-plaque brachytherapy for uveal melanoma
    Michelle R. Tamplin
    Jui-Kai Wang
    Anthony H. Vitale
    Ryuya Hashimoto
    Mona K. Garvin
    Elaine M. Binkley
    Daniel E. Hyer
    John M. Buatti
    H. Culver Boldt
    Randy H. Kardon
    Isabella M. Grumbach
    BMC Ophthalmology, 22